(Q35620727)

9 August 2017

1 reference

title

Diabetic renal disease: from recent studies to improved clinical practice (English)

1 reference

9 August 2017

Mogensen CE

1

1 reference

PubMed ID

14706048

9 August 2017

Cooper ME

series ordinal

2

1 reference

9 August 2017

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

21

1 reference

9 August 2017

1

1 reference

9 August 2017

4-17

1 reference

Pathogenesis, prevention, and treatment of diabetic nephropathy.

9 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Renoprotection by angiotensin-receptor blockers and ACE inhibitors in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Hypertension and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Aldosterone in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Role of nephrin in renal disease including diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Prevention of diabetic renal disease with special reference to microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Contrasting renal functional reserve in very long-term Type I diabetic patients with and without nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

British Hypertension Society guidelines for hypertension management 1999: summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Rebound sodium and water retention occurs when diuretic treatment is stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Restriction of dietary protein and progression of renal failure in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Renoprotective effects of a novel inhibitor of advanced glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

Pathophysiology of Progressive Nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01121.X

10.1111/J.1464-5491.2004.01121.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14706048